全部

1·Classification of Hematological Malignancies Based on Pathogenesis Molecules or Abnormal Pathways.

血液系统恶性肿瘤分子发病原理或异常信号途径分型。

2·The selective inhibitors of NOS, COX, or the both may provide a new approach for the treatment of hematological malignancies.

针对NOS、COX或两者的选择性抑制剂为血液系统恶性肿瘤的治疗提供了新的线索。

3·Objective to evaluate the clinical outcome of autologous hemopoietic stem cell transplantation (AHSCT) for hematological malignancies.

目的评价自体造血干细胞移植(AHSCT)治疗恶性血液病的疗效。

4·Objective to investigate the epidemiological characteristics and drug resistance profile of the infection in patients with hematological malignancies.

目的了解血液肿瘤合并感染病原菌分布的特点及耐药性变化。

5·Objective Expoloring the detection of minimal residual malignant cells in bone marrow from children with hematological malignancies to predict the prognosis.

目的探讨以恶性血液肿瘤患儿骨髓微量残留病检测预测预后的可能性。

6·Conclusion Phenylbutyrate combined with other differentiation agents may be an effective differentiation therapy in a proportion of hematological malignancies.

结论苯丁酸钠和其它诱导分化剂联合应用可能是部分血液肿瘤有效的诱导分化治疗方法。

7·These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

这些抗体以及使用这些抗体的新方法可用以治疗例如血液恶性肿瘤，例如多发性骨髓瘤。

8·The growth of tumor cells can be inhibited by the anti-SDF-1 antibody or anti- CXCR4 antibody, supporting a new way for the therapy against hematological malignancies.

用SDF-1 抗体或CX-CR4抗体能有效的抑制肿瘤细胞的生长，为治疗血液系统肿瘤开辟了新途径。

9·The generation and development of hematological malignancies are close related to vasculogenesis, so it is an important tactic of anti-vessel growth therapy in hematological malignancies.

抗血管生成治疗已经成为治疗恶性血液疾病的重要策略。